Elevance Health, Inc. filed a current report on September 10, 2026, disclosing that company officers plan to reaffirm full year 2026 earnings and benefit expense ratio guidance during upcoming investor and analyst meetings.
Key Highlights
- GAAP earnings guidance reaffirmed: Shareholders' earnings expected to be at least $20.10 per diluted share for full year 2026.
- Net unfavorable items: The $20.10 per diluted share figure includes approximately $6.90 per diluted share of net unfavorable items.
- Adjusted earnings guidance reaffirmed: Adjusted shareholders' earnings expected to be at least $27.00 per diluted share for full year 2026.
- Benefit expense ratio guidance: Full year 2026 benefit expense ratio guidance reaffirmed at 90.2% plus or minus 50 basis points.
- Scope of guidance: The guidance does not include any adjustment items beyond those reported in the company's second quarter 2026 earnings.
Elevance Health Officers to Reaffirm 2026 Financial Guidance in Investor Meetings
Elevance Health, Inc. (NYSE:ELV) submitted a Regulation FD disclosure on September 10, 2026, indicating that company officers "expect to speak with investors and analysts over the next several weeks." According to the filing, those discussions will center on reaffirming previously issued full year 2026 financial guidance rather than introducing new projections.
The filing states that shareholders' earnings guidance for full year 2026 is expected to be "at least $20.10 per diluted share," which the company disclosed includes "approximately $6.90 per diluted share of net unfavorable items." Excluding those items, the company reported it "continues to expect adjusted shareholders' earnings to be at least $27.00 per diluted share." The filing specifies that this guidance does not include any adjustment items beyond those already reported in the second quarter 2026 earnings.
Separately, the filing notes that officers will also reaffirm full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. The filing contains forward-looking statements, which the company cautions are "subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially." The disclosure was signed by Kathleen S. Kiefer, Chief Governance Officer and Corporate Secretary.
What Was Disclosed
Elevance Health filed a Regulation FD current report on September 10, 2026, disclosing that officers plan to reaffirm full year 2026 shareholders' earnings guidance of at least $20.10 per diluted share and adjusted earnings guidance of at least $27.00 per diluted share, along with a benefit expense ratio of 90.2% plus or minus 50 basis points.




Please wait processing your request...